Project Optimus transforms cancer treatment by optimizing dosing strategies, enhancing efficacy, and reducing toxicities in modern therapies.
Kevin Cheng, PharmD
Advertisement
Articles by Kevin Cheng, PharmD
Kevin Chen, PharmD, MS, BCOP, CPP; and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the newly approved drug taletrectinib.
The data highlight novel therapies and biomarkers shaping personalized cancer care.
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Advertisement
Latest Updated Articles
Project Optimus and Its Impact on the Oncology Treatment LandscapePublished: December 5th 2025 | Updated:
Implementing Datopotamab Deruxtecan in Practice: TROPION InsightsPublished: December 5th 2025 | Updated:
Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic CancersPublished: July 16th 2025 | Updated:
Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLCPublished: July 30th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Can Close the Opioid Addiction Care Gap
2
Once-Weekly Retatrutide Reduces Weight and Knee Pain in Patients With Obesity and Osteoarthritis
3
FDA Approval Signals Broader Recognition of Sexual Health in Aging Women
4
FDA Approves T-DXd With Pertuzumab for First-Line Treatment of Advanced HER2+ Breast Cancer
5
